A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 370-377

  Morrison, Dennis ^a   Legg, Thomas J ^a   Billings, Christopher W ^a   Forrat, Remi ^b   Yoksan, Sutee ^c   Lang, Jean ^b  

^a Bio Kinetic Clinical Applications   (United States)

^b SANOFI PASTEUR   (France)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; SODIUM CHLORIDE; VIRUS ANTIBODY;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SEROTYPE; SIDE EFFECT; VACCINATION; VIREMIA; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; BLOOD; CLASSIFICATION; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; SEROTYPING; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTYPING; VIREMIA; YOUNG ADULT;

EID: 75649131888     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649916     Document Type: Article

References (22)

1. Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res 1999; 53: 35-70.
2. Halstead SB. Dengue. Lancet 2007; 370: 1644-6452.
3. Kroeger A, Nathan MB. Dengue: setting the global research agenda. Lancet 2006; 368: 2193-2195. (Pubitemid 44958999)
4. Monath TP. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 1994; 91: 2395-2400.
5. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global burden of disease and risk factors. Oxford: Oxford University Press, 2006.
6. Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008; 31: 239-252. (Pubitemid 351315114)
7. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2: 60-67. (Pubitemid 43927159)
8. Kanesa-Thasan N, Morrison D, Forrat R, Deary A, McCarthy K, Nichols R. Safety, viremia and immunogenicity of a tetravalent live attenuated Chimerivax dengue vaccine in healthy US adults. Am J Trop Med Hyg 2005; 73 (suppl 6): 116.
9. Kanesa-Thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19: 3179-3188. (Pubitemid 32324047)
10. Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006; 24: 1238-1241. (Pubitemid 43222030)
11. Rothman AL, Kanesa-Thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001; 19: 4694-4699. (Pubitemid 32800752)
12. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66: 264-272. (Pubitemid 34756095)
13. Sanchez V, Gimenez S, Tomlinson B, et al. Innate and adaptive cellular immunity in fiavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006; 24: 4914-4926. (Pubitemid 43782690)
14. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23: 99-109. (Pubitemid 38222779)
15. Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78: 4761-4775. (Pubitemid 38501097)
16. Mantel N, Aguirre M, Gulia S, et al. Standardized quantitative RTPCR assays for quantitation of yellow fever and chimeric yellow feverdengue vaccines. J Virol Methods 2008; 151:40-46.
17. Porterfield JS. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg 1959; 53: 458-466.
18. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99: 285-290.
19. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses.Viral Immunol. 2008; 21(2): 123-132.
20. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; l(1): 30-50.
21. Guy B, Barban V, Mantel M, Aguirre M, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80(2): 302-311.
22. Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26: 5712-5721.